Harry Robb

Harry Robb is currently an Analyst at Lifespan Vision Ventures since June 2023 and holds multiple roles as a Board Observer at Matter Bio, Bolden Therapeutics, and LIfT BioSciences from February and September 2024 respectively. Previously, Harry served as the Deal Origination & Capital Raising Manager and subsequently as Deal Origination & Capital Raising Executive at Longevity.Technology from September 2021 to June 2023. Earlier experience includes a position as a Research Analyst at FLYFWD Ventures from June 2020 to September 2021, a Business Development Intern at OXWASH from May 2020 to January 2021, and a Healthcare Intern at Azalee Group in late 2019. Harry Robb holds an MSc in Applied Biosciences and Biotechnology from Imperial College London and a BSc (Hons) in Biomedical Sciences from King's College London. Education was completed at Lancaster Royal Grammar School.